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.Q '0 Abstract 
Vaults are large ribonucleoprotein particles believed to be involved in multidrug resistance 
and intracellular transport. The vault complex consists of three proteins and non-coding vault 
RNAs. It has been shown that the non-coding vault RNA encodes regulatory small vault RNAs 
(svRNAs). These svRNAs associate with the RNA-induced silencing complex and regulate gene 
expression similarly to microRNAs. It is unknown which genes the svRNAs regulate, but they are 
thought to regulate genes relating to multidrug resistance and intracellular antigen transport. I have 
selected several genes of interest relating to cancer, multidrug resistance, inflammation, and the 
autoimmune response to predict whether the svRNAs regulate these genes. Since the svRNAs 
regulate genes similarly to micro RNA, I used micro RNA target prediction tools to find potential 
functional binding sites for the svRNAs in the 3' untranslated regions of the selected gene 
messenger RNAs. I found several target sites that have a very high potential to be functional binding 
sites for the svRNAs. These results can be used to conduct experiments to verify that the svRNAs 
bind to the predicted target sites and regulate the expression of the targeted gene. 
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Introduction 
MicroRNAs 
MicroRNAs (miRNAs) are highly conserved small non-coding RNAs, usually about 22 
nucleotides in length, which regulate gene expression. Tbis regulation takes place mosdy by targeting 
the 3' untranslated region (3' UJR) of messenger RNAs (mRNAs). miRNAs guide the RNA-
induced silencing complex (RISC) to target sites in the mRNA that have reverse complementary 
sequences with the miRNA (5' end of miRNA is aligned with 3' end of mRNA, and vice versa) 
(Hofacker, 2007). When the RISe, bound with a miRNA, finds a complementary match, it 
suppresses the translation of the target mRNA, or degrades the mRNA with the use of ribonuclease. 
Both of these actions prevent the creation of the protein that the target mRNA codes for. 
The complementarity between miRNAs and target sites on mRNAs are far from perfect 
matches though. The defining part of a miRNA-mRNA match is a short seed region of 6-8 
nucleotide bases. Tbis seed region is located on the 5' end of the miRNA at nucleotide positions 2 
through 9. The seed region of the miRNA is sometimes the only part of the sequence that is 
perfecdy base-paired with the mRNA. As such, these seed matches are used by miRNA target 
prediction algorithms to find potential binding sites on mRNAs (Hofacker, 2007). Because using 
such a short seed region to find target sites will produce many false positive hits, the miRNA target 
prediction algorithms must use some other data to produce reliable predictions. Many methods, 
such as PicTar and TargetScan, rely heavily on evolutionary conservation of the target site to 
determine the likelihood of a positive match. But evolutionary conservation is not useful for species-
specific miRNAs, and it does not address the mechanism by which the miRNAs find their target 
mRNAs in the cell (Hofacker, 2007). 
Kertesz et of developed a new algorithm, called Probability of Interaction by Target 
Accessibility (PITA), to predict miRNA targets using free energy calculations of the miRNA-mRNA 
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bindings instead of evolutionary conservation. These same free energy calculations are used by 
several algorithms to predict the minimum free energy (MFE) RNA secondary structures. According 
to the principle of minimum energy, which is a restatement of the second law of thermodynamics, 
RNA will form secondary structures that minimize the free energy of the system. The PITA 
algorithm calculates three different free energies at a target mRNA site to predict the site 
accessibility. Previous methods for miRNA target prediction scored interactions based on only the 
free energy gained by binding of the miRNA to the mRNA target sequence. This free energy 
measurement is called ~Gduplcx. The PITA first calculates this ~Gduplcx, but does not stop there like 
previous algorithms. Next, the PITA algorithm calculated the free energy lost by unpairing the 
mRNA target site from its RNA secondary structure, called ~Gopcn. The PITA algorithm uses the 
free-energy secondary structure prediction algorithm of (Zuker and Stiegler, 1981) from the Vienna 
RNA Package to predict the mRNA's secondary structure, which it then uses to find ~Gopcn. The 
PITA algorithm then takes the difference between ~Gduplcx and ~Gopcn to assign an energy-based 
score, called MG, for the miRNA-mRNA association. Kertesz et oJ. found that their PITA 
algorithm predicted miRNA targets better than all of the previous miRNA target prediction 
algorithms (most of which use evolutionary conservation filters). The integration of site accessibility 
in miRNA target prediction represents a measurable improvement and a simplification over existing 
methods (Kertesz et oJ. 2007). 
Genes were once thought of almost exclusively as instructions for building proteins, but now 
scientists' perception of them is changing. Genes are now seen as RNA factories, not just protein 
instruction sets ("Really New Advances," 2007). In fact, genes for protein may actually be in the 
minority. According to Isidore Regoutsos, IBM's genome-miner in chief, there may as many as 
37,000 miRNAs in humans, while there are 21,000 protein-encoding genes in humans. It is now 
thought that miRNAs regulate expression of the majority of genes in the human genome (peter, 
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2010). The existence of miRNAs may also explain how some organisms are more complex than 
others, even though most animals have around 20,000 genes. If complexity was just related to the 
number of genes in an organism, then we would not be able to explain the increased complexity in 
some organisms, such as humans. But with the new knowledge of RNA gene regulation, we may be 
able to begin to explain the differences in organism complexity based on the role RNA plays in gene 
regulation in the more complex organisms. 
Vaults 
Vaults are large ribonucleoprotein particles implicated in multidrug resistance and 
intracellular transport. The vault complex is the largest ribonucleoprotein particle described to date, 
with a molecular mass of 13 MDa, approximately three times the size of a ribosome (van Zon ct aL, 
2001). Vaults are conserved organelles, found in many diverse eukaryotic cells, including in 
mammals, birds, fish, echinoids, and slime molds (persson ct al. 2009). Discovered in 1986, the 
structures were named vaults because their morphology resembled the arches of vaulted ceilings in 
cathedrals. Vaults form hollow barrel-like structures that are symmetrical and have an invaginated 
waist and two protruding caps at each end (van Zon ct ai, 2001). Three proteins make up the vault 
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complex - the major vault protein (MVP), poly(ADP-ribose) polymerase 4 (p ARP4/vPARP), and 
telomerase-associated protein 1 (TEP1). The barrel-like waist of the vault particle is made up of 96 
MVP molecules. The protruding caps on the end of vault particle are made up of 8 P ARP4 
molecules and 2 TEPl molecules (van Zon et ai, 2(01). The vault complex also contains non-coding 
vault RNA. While the three vault proteins are structural components of the vault complex, the vault 
RNA instead plays a functional role. 
Persson et aL found that vault RNAs could theoretically fold into structures resembling 
microRNA precursors, so they decided to investigate whether the vault RNA could be a new source 
of small regulatory RNAs. They found that multiple regulatory small vault RNAs (svRNAs) were 
encoded by the vault RNA. The svRNAs were produced by a Dicer-dependent but Drosha-
independent mechanism (persson et aL, 2(09). Dicer is a component of the microRNA pathway, so 
Persson et aL tested to see whether the svRNAs participated in the RISC complex like microRNAs. 
They found that the svRNAs could indeed participate in the RISC complex, regulating gene 
expression similar to miRNAs. Approximately 80% of vault RNA is free in the cytosol, suggesting 
that the svRNAs could be processed from the accessible cytosolic vault RNA, without the presence 
of the vault organelle. 
Vault particles have been found to be up-regulated in multidrug-resistant cancer cell lines 
(Kickhoefer, 1998). Multidrug resistance is the major cause of chemotherapy failure in cancer 
treatment, and is an important current field of research. Multidrug-resistant cancer cells frequendy 
overexpress a protein that was originally named the Lung Resistance-related Protein. Investigation 
of this protein revealed it was the human homologue of the Major Vault Protein (Scheffer et aL, 
1995). The MVP has since been shown to be overexpressed in many multidrug-resistant tumor cell 
lines, including SW1573/2R120 non-small cell lung cancer, GLC4/ ADR small cell lung cancer, 
MCF-7/MR breast cancer, and 8226/MR20 myeloma (Kickhoefer, 1998). It has been shown that 
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the overexpression of the MVP alone is not enough to confer multi-drug resistance, which is not 
unexpected since MVP comprises only 70% of the vault particle. The minor vault proteins and the 
vault RNA (including the regulatory svRNAs) could also be required for drug resistance to occur. 
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Selected Gene Messenger RNAs 
PTGS-1 (COX-1) - Homo sapiens prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase) (PTGS1), transcript variant 1, mRNA (NCBI Accession: 
NM_000962.2) 
Prostaglandin-endoperoxide synthase, also known as Cyclooxygenase, is the central enzyme 
in the biosynthesis of prostaglandins. PTGS-l encodes the first isozyme of Cyclooxygenase. 
Prostaglandins play an important role in inflammation, as well as other functions in animals. Because 
of its large role in inflammation, I chose to predict svRNA target sites in the 3' UTR of the PTGS-l 
gene. 
PTGS-2 (COX-2) - Homo sapiens prostaglandin-endoperoxide synthase 2 (prostaglandin G /H 
synthase and cyclooxygenase) (PTGS2), mRNA (NCBI Accession: NM_OO0963.2) 
PTGS-2 encodes the second isozyme of Cyclooxygenase. It differs from the first isozyme 
because it is an inducible enzyme and is regulated by specific stimulatory events. PTGS-2 is 
upregulated in many cancers, and can stimulate cancer progression. Because of its role in 
inflammation and its link to cancer, I chose to predict svRNA target sites in the 3' UTR of the 
PTGS-2 gene. 
TEP1 - Homo sapiens telomerase-associated protein 1 (TEP1), mRNA (NCBI Accession: 
TEPl is a minor vault protein that forms part of the vault structure, at the end caps of the 
vault. TEPl is required for a stable association of the vault RNA with the vault particle, and helps 
recruit free vault RNAs to the vault particle (Kickhoefer et 01, 2001). Therefore, target sites for the 
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small vault RNAs may exist in the TEPl gene, in order to recruit the vault RNA into the vault 
particle. For this reason, I chose to predict svRNA target sites in the 3' UTR of the TEPl gene. 
NF- xB - Nuclear factor kappa-light-chain-enhancer of activated B cells 
NF-xB is a protein complex that controls the transcription of DNA. NF-xB regulates many 
genes involved in inflammation and the immune system. Incorrect regulation of NF-xB has been 
linked to cancer, inflammatory and autoimmune diseases, and improper immune development. NF-
xB is also a regulator of genes that control cell proliferation and cell death, protecting cells from 
conditions that cause apoptosis. In tumor cells, NF-xB is active due to mutations in genes that 
encode NF-xB or genes that control NF-xB activity. lbis causes the tumor cells to maintain cell 
proliferation, preventing apoptosis and allowing the cancer to progress. There are five proteins in 
the mammalian NF-xB complex: NF-xBl, NF-xB2, RelA, Rem, and c-Rel. Because of the NF-xB 
complex's role in inflammation, the immune system, and the proliferation of cancer cells, I chose to 
predict svRNA target sites in the 3' UTR regions of the 5 genes that encode the 5 NF-xB proteins. 
These genes are NFKBl (NCB I Accession: NM_OO3998.3), NFKB2 (NCB I Accession: 
NM_001077494.1), RELA (NCBI Accession: NM_021975.3), RELB (NCBI Accession: 
NM_OO6509.2), and REL (NCB I Accession: NM_002908.2). 
NLRP1- Homo sapiens NLR family, pyrin domain containing 1 (NLRP1), transcript variant 1, 
mRNA (NCBI Accession: NM_033004.3) 
The NLRPl gene encodes a member of the Ced-4 family of apoptosis proteins. Ced-family 
members are known to be a key mediator of programmed cell death. Overexpression of the NLRPl 
gene was demonstrated to induce apoptosis in cells. Because of its strong connection to apoptosis in 
cells, I chose to predict svRNA target sites in the 3' UTR region of NLRP1. 
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PRKAeB - Homo sapiens protein kinase, cAMP-dependent, catalytic, beta (PRKACB), transcript 
variant 1, mRNA (Accession: NM_182948.2) 
The PRKACB gene encodes the cAMP-dependent protein kinase catalytic subunit beta, 
which is an enzyme that is part of the cAMP-dependent pathway. Cyclic adenosine monophosphate, 
or cAMP, is a second messenger that is important in many cell functions, and is involved in the 
activation of protein kinases. Some research has suggested that deregulation of the cAMP pathways 
is linked to the growth of some cancers. PRKACB was found to be strongly upregulated in MCF-7 
cancer cells, and was within the top 100 predicted target sites of svRNAb (persson et ai, 2009). 
Because of its link to cancer growth and its high svRNAb target site prediction, I chose to predict 
svRNA target sites in the 3' UTR region of the PRKACB gene. 
IL10 (Interleukin 10) - Homo sapiens interleukin 10 (ILl0), mRNA (Accession: NM_OOO572.2) 
The ILlO gene encodes the protein Interleukin 10, which is an anti-inflammatory cytokine. 
Interleukin 10 has effects in immunoregulation and inflammation. It also enhances cell survival, 
proliferation, and antibody production. Interleukin 10 can inhibit the synthesis of many pro-
inflammatory cytokines, and can block activity in the NF-xB complex. ILl 0 was found to be 
strongly upregulated in MCF-7 cancer cells (persson et al, 2009). Because of its effects on 
immunoregulation and inflammation, as well as its potential role in cell proliferation and antibody 
production, I chose to predict svRNA target sites in the 3' UTR region of the ILl 0 gene. 
CXCL14 - Homo sapiens chemokine (C-X-C motif) ligand 14 (CXCL14), mRNA (Accession: 
NM_004887.4) 
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The CXCL14 gene encodes the cytokine Chemokine ligand 14, as known as breast and 
kidney-expressed chemokine (BRAK). CXCL14 plays a role in inflammation and the immune 
system, by activating monocytes when in the presence of the inflammatory mediator prostaglandin-
E2. CXCL14 was found to be strongly upregulated in MCF-7 cancer cells (persson et al, 2009) 
Because of its effects on inflammation and the immune system, I chose to predict svRNA target 
sites in the 3' UTR region of the CXCL14 gene. 
ATP-binding cassette transporters (ABC-transporters) 
ABC-transporters are a superfamily of transmembrane proteins that utilize the energy of 
adenosine triphosphate (A TP) hydrolysis to translocate various substrates across cell membranes. 
They transport a wide variety of substrates across extracellular and intracellular membranes. Some of 
the ABC-transporters transport drugs across these membranes, and playa role in multidrug 
resistance. The remaining genes encode proteins of this superfamily that are potentially involved in 
drug transport and multidrug resistance. I chose to predict svRNA target sites on the genes because 
of their role in multidrug-resistance. 
ABCC2 - Homo sapiens ATP-binding cassette, sub-family C (CFIR/MRP), member 2 (ABCC2), 
mRNA (Accession: NM_000392.3) 
The ABCC2 gene encodes the Canalicular multispecific organic anion transporter 1 protein, 
which is an ABC-transporter protein. The ABCC2 protein is a member of the multidrug resistance 
protein (MRP) subfamily, which is involved in multidrug-resistance. The substrates that ABCC2 
transport include anticancer drugs such as vinblastine. ABCC2 appears to be involved in drug 
resistance in mammalian cells. 
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ABCC4 - Homo sapiens ATP-binding cassette, sub-family C (CFfR/MRP), member 4 (ABCC4), 
transcript variant 1, mRNA (Accession: NM_OOS84S.3) 
The protein encoded by the ABCC4 gene is an ABC-transporter protein, and is a member of 
the multidrug resistance protein (MRP) subfamily, which is involved in multidrug resistance. ABCC4 
transports organic anions, and has been found to transport cAMP (discussed above) ( van Aubel et al, 
2002). 
ABCBt (P-glycoprotein) - Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 (ABCB1), mRNA (Accession: NM_OO0927.3) 
The ABCB1 gene encodes the ABC-transporter protein P-glycoprotein (pGP). PGP is a 
member of the multidrug resistance protein (MRP) subfamily, which is involved in multidrug 
resistance. PGP transport many substrates, including chemotherapeutic agents such as doxorubicin 
and vinblastine. 
ABCG2 - Homo sapiens A TP-binding cassette, sub-family G (WHIlE), member 2 (ABCG2), 
mRNA (Accession: NM_004827.2) 
The ABCG2 gene encodes the ATP-binding cassette sub-family G member 2 protein, also 
known as the breast cancer resistance protein. ABCG2 functions as a xenobiotic transporter which 
may playa role in multidrug resistance. 
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Methods 
After selecting the genes to do svRNA target predictions on, I used the National Center for 
Biotechnology Information (NCB!) Entrez Global Query Cross-Database Search System to find the 
gene sequences. Once I located the gene in the Entrez Gene database, I navigated to mRNA entry 
for the gene in the Entrez Nucleotide database. The Entrez Nucleotide database lists the entire 
mRNA transcript for the gene, but I only wanted to run predictions on the 3' UTR region of the 
gene. The Entrez Nucleotide entry for the gene lists the nucleotide positions of the coding sequence 
(CDS) of the gene. The coding sequence is the part of the gene's mRNA that is translated into the 
protein. The 3' UTR is located after the stop codon in the coding sequence on the 3' end of the 
mRNA. Knowing the ending nucleotide position of the coding sequence allowed me to find where 
the 3' UTR region of the mRNA started. I then selected the nucleotides from the end of the coding 
sequence until the end of the mRNA sequence from the F ASTA formatted sequence on the NCBI 
website. This selected sequence includes the 3' UTR and the poly-A tail of the gene's mRNA. 
The stNcture of a typical human protein coding mRNA including the untranslated regions (UTRs) 





Next, I used to the Segal Lab of Computational Biology'S online microRNA prediction tool 
to predict svRNAa and svRNAb target sites in the selected genes' 3' UTR ("Online microRNA 
prediction tool"). The online microRNA prediction tool uses the Probability of Interaction by 
Target Accessibility algorithm developed by Kertesz et aL to find and score the target sites. I set the 
seed parameters for the prediction tool to find seed matches of 6 to 8 bases in length, with a single 
G: U wobble pair allowed, and no mismatches allowed. The recommended seed parameter settings 
are to consider seeds length 6 to 8 bases, with no mismatches, and up to one G:U wobble pair in 7-
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or 8-mers. Since I allowed a wobble base pair in 6-mer seed matches in the parameters I used, there 
is a potential for false positives, and 6-mer seed matches with a wobble pair (6:0:1) in the results 
should be scrutinized more than the other matches. The more negative that the score assigned by 
the PITA algorithm (MG) is, the more likely that the micro RNA (or svRNA in this case) will 
actually bind to the target site in natural circumstances. As a rough rule of thumb, sites with MG 
values below -10 are likely to be functional in endogenous microRNA (svRNA in this case) 
expression levels, although with very high expression levels, sites with MG above -10 may be 
functional as well. PITA's notation of the seed column results (X:Y:Z) represent the size of the seed 
(X), the number of mismatches (y), and the number of G:U wobble pairs (Z). 
Once I got the PITA seed match results for all of the selected genes from the online 
microRNA prediction tool, I began the svRNA-mRNA alignments for the target sites predicted by 
the PITA algorithm. First, I manually aligned the 22nt (svRNAa matches) or 23nt (svRNAb 
matches) sequences from the mRNA at the target site with the svRNAs in an one-to-one straight 
alignment (each nucleotide position in the svRNA sequence matched up with the same position in 
the mRNA sequence, with no gaps). Although this straight alignment is not usually how the svRNA 
would actually bind to the target RNA, it gives a general first look at the svRNA next to the target 
site on the mRNA. 
Next I used the RNAfold web server (which uses the Zuker and Stiegler algorithm) from the 
Vienna RNA Web suite (Gruber ct ai, 2008) to find the MFE binding configuration of the svRNA to 
the mRNA target site. The RNAfold program takes a single RNA sequence as its input and 
calculates the MFE secondary structure of that RNA sequence. Since I needed to find the MFE 
binding between two RNA sequences (the svRNA sequence and the mRNA target site sequence), I 
combined the two sequences together with four N's and gave folding constraints that required the 
seed regions of the two sequences to bind together. This forced the RNAfold algorithm to fold the 
12 
combined RNA sequence into a stem-loop structure around the four N's I inserted. lbis results in 
the MFE binding between the svRNA and the mRNA target site, which is most likely how they 
would bind in nature according to the minimum energy principle. A visual representation of the 
MFE predicted structure is output by RNAfold, and the base pairs are colored according to their 




Gene microRNA Position Seed ~Gduple. 
PTSG-13' UTR svRNAa 3070 6:0:0 -23.8 
PTSG-1 3' UTR svRNAb 2836 6:0:1 -17.1 
PTSG-1 3' UTR svRNAb 2390 8:0:1 -23.83 
PTSG-13' UTR svRNAb 3062 7:0:1 -14.1 
PTSG-13' UTR svRNAa 816 7:0:1 -19.2 
PTSG-13' UTR svRNAb 647 6:0:1 -16.4 
PTSG-13' UTR svRNAb 2963 6:0:0 -14.55 
PTSG-1 3' UTR svRNAa 1630 6:0:1 -12.4 
PTSG-13' UTR svRNAb 1732 6:0:1 -14.25 




5' CUCCUGCCUGAGUUUCCAGCCU 3' <- PTGS-l 
: I I : I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
5005 
I 
5' CUCCUGCCUGAGUU---UCCAGCCU 3' <- PTGS-l 
I: I I I I I I I I I I I I I I : 
















5 ' UAUUUGUCAGUUUGGUUGGGCUA 3' <- PTGS-1 
I : I . I : I I : I I I I . 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNA fold MFE Predicted Alignment 
4771 
I 
5' UAUUUGUC--AGUU-UGGUUGGGCUA 3' <- PTGS-1 
I I I I I I I : I : I I : I I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 




5' AAGCCUUUAUGGCUGCUGGGCUG 3' <- PTGS-1 
I I I : : I : I I I I : I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
4325 
I 
5' AAGCCUUUAUGGCUGCUGGGCUG 3' <- PTGS-1 
I : : I : I I I I : I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
15 




5' GCCAUCGACUCCUGCCUGAGUUU 3' <- PTGS-1 
: : I I I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
4997 
I 
5' GCCAUCGACUC--CUGCCUGAGUUU 3' <- PTGS-1 
I I I I I : I I I I I I : I 
3' GACAGCUUCAUUGGC-GACUCGAU 5' <- svRNAb 




5' AACACUGGAACAUGGCUAGCCU 3' <- PTGS-1 
I I I I I : I: I I : I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
2751 
I 
5' AACACUGGAACAUGGCUAGCCU 3' <- PTGS-1 
I I I I : : I I : I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
16 




5' AUGUAGAGAGAACAGGUGGGCUG 3' <- PTGS-l 
III II: 1111111:111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
2 582 
I 
5' AUGUAGAGAGAACAGGUGGGCUG 3' <- PTGS-l 
III II: 1111111:111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 




5' ACUUAAAUAAUUUGGGUGAGCUG 3' <- PTGS-l 
I I : I 111111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
4898 
I 
5' ACUUAAAUAAUUUGGGUGAGCUG 3' <- PTGS-l 
1111111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
17 




5' AGACAGCCCUCCACUCCAGCUC 3' <- PTGS-l 
I I I I I I I : I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3565 
I 
5 ' AGACAGCC-CUCCACU----CCAGCUC 3' <- PTGS-l 
: I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5 ' <- svRNAa 




5' UUCAUGAUCCACACUUUGGGCUU 3' <- PTGS-l 
: I : I I I I: I I : I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNA fold MFE Predicted Alignment 
3667 
I 
5' UUCAUGAUCCACACU-UUGGGCUU 3' <- PTGS-l 
: I I I I: : I I : I I I 
3' GACAGCUUCAU-UGGCGACUCGAU 5' <- svRNAb 
18 
PTGS-l Result Remarks 
PTGS-1 has some very promising seed matches that seem highly likely to be functional. The 
best scoring seed match, at position 5005, seems very promising with a very high LlGduplex value of 
-23.80 and a MG value of -16.07. In the predicted MFE binding structure, all but 5 of the svRNAa 
bases pair with the target site, and all the base pairs have very high base pair probability. 
The second best scoring seed match, at position 4771, is also a good potential to be a 
functional match with MG value of -10.6 and LlGduplcx value of -17.10. It is a 6-mer seed match with 
a wobble base pair, so the seed may not be a very strong bond, but in its predicted MFE structure all 
but 6 bases bind with the target site, so the overall binding seems promising. 
The third best scoring seed match, at position 4325, also seems very promising with a high 
LlGduplex value of -23.83 and MG value of -9.61. In its predicted MFE structure, it has 14 base pairs 
in a row, which would form a very strong bond. 
I would recommend further investigation into these three target sites to determine whether 
they are functional binding locations for svRNAa (position 5005) and svRNAb (position 4771 and 
4325). The fourth best scoring seed match (position 4997) overlaps with the seed match at position 
5005 and has a much less MG and LlGduplex value, so it unlikely to be functional binding site. The 




Gene microRNA Position Seed 
PTGS-2 3' UTR svRNAa 2100 6:0:1 -17.4 -7.6 
PTGS-2 3' UTR svRNAa 2002 7:0:1 -16.6 -10.92 
PTGS-2 3' UTR svRNAb 239 6:0:1 -10.5 




5' GCUUCGUUAAUUUGUUCAGCCA 3' <- PTGS- 2 
: I: I I:: I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' GCUUCGUUAAUUUGUUCAGCCA 3' <- PTGS-2 
I I I I: I I I I: I I I I I 
3' UGGCGACUCGAUUU--C-GGUCGGG 5' <- svRNAa 




5' GGAUAGGCCUAUGUGCUAGCCC 3' <- PTGS- 2 
I : 11:11111 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3954 
I 
5' GGAUAGGCCUAUGUGCUAGCCC 3' <- PTGS-2 
I III 11:11111 









5' AUAAACCAGAGAGAAAUGAGUUU 3' <- PTGS-2 
I I I : I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
2191 
I 
5' AUAAACCAGAGAGA--AAUGAGUUU 3' <- PTGS-2 
I I I : I I I I I: I 
3' GACAGCUUCAUUGGCGACUCGAU 5 ' <- svRNAb 
PTGS-2 Result Remarks 
The best scoring seed match at position 4052 seems like a probable candidate for functional 
binding. Although it is a 6-mer seed match with a G:U wobble pair, it has low ~Gduplex and MG 
value, and all but 6 of the svRNAa bases pair with the target site in the predicted MFE 
configuration. All of the base pairs have a very high base pair probability as well, so this seed match 
is a good candidate for a functional binding and should be further investigated and tested. 
The other two predicted seed matches have high MG values and are most likely not able to 
form functional binding. The base pair probabilities of the base pairs outside the seed region in the 
MFE configurations for both matches are fairly low, and both matches only have around 50% of the 
bases in the svRNA pairing to the target site. Therefore, these matches are probably not functional 
binding sites. 
21 
Gene microRNA Position Seed 6Gduplex 6Gopen 
TEP13' UTR svRNAa 1306 6:0:1 -15.41 
TEP13' UTR svRNAa 1350 6:0:1 -20.4 
TEP13' UTR svRNAa 1216 6:0:1 -18.19 
TEP13' UTR svRNAa 2177 6:0:1 -12.51 
TEP13' UTR svRNAa 1449 6:0:0 -15.92 
TEP13' UTR svRNAa 694 6:0:1 -18.9 
TEP13' UTR svRNAb 1770 7:0:1 -14.2 
TEP13' UTR svRNAa 776 6:0:0 -19.34 
TEP13' UTR svRNAb 1738 6:0:1 -10.36 
TEP13' UTR svRNAb 2471 6:0:1 -13.1 




5' GGUUAUCUGCACACCUCAGCCU 3' <- TEPI 
I I I I : I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNA fold MFE Predicted Alignment 
9230 
I 
5' GGUUAUCUGCACACCUCAGCCU 3' <- TEPI 




























5' CGUGAGCCAUUGUGCCCGGCCC 3' <- TEP1 
: I : I: : I I : I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
9274 
I 
5' CG-UGAGCCAUUGUGCCCGGCCC 3' <- TEP1 
I I I I I I I I I I : I I I I 
3' UGGCGACUCG--AUUUC-GGUCGGG 5' <- svRNAa 




5' UGCCCACCACCACGCCCAGCUA 3' <- TEP1 
I I I I : I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
9140 
I 
5' UGCCCACCACCACGC-----CCAGCUA 3' <- TEP1 
I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
23 




5' UUAUAUAAAAGCAUCCCAGCUA 3' <- TEP1 
:: : I I I I I I I I : 
3' UGGCG-ACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNA fold MFE Predicted Alignment 
10101 
I 
5' UUAUAUAAAAGCAUC--CCAGCUA 3' <- TEP1 
I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' CGGGCACCUGUAGUCCCAGCUA 3' <- TEP1 
I I I I : I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
9373 
I 
5' CGGGCACCUGUAGU----CCCAGCUA 3' <- TEP1 
: I I I I I I : I I I I I: 
3' UGGCGAC-UCGAUUUCGGUCGGG 5' <- svRNAa 
24 




5' UCCUCCUCUGUUACUCCAGCCU 3' <- TEP1 
I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNA fold MFE Predicted Alignment 
8618 
I 
5' UCCUCCUCUGUUACU---CCAGCCU 3' <- TEP1 
I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' AGACACCACUGCACUCCAGCCU 3' <- TEP1 
I I: I I I I I I I: 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
8700 
I 
5' AGACACCACUGCACU----CCAGCCU 3' <- TEP1 
I I I I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
25 




5 ' GGGAGUUAAAGGGCACUGAGUUU 
I I .. I I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 
RNAfold MFE Predicted Alignment 
9694 
I 
3' <- TEPI 
5' <- svRNAb 
5' GGGAGUUAAAG-GGC-ACUGAGUUU 3' <- TEPI 
I I I I I :: I I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 




5' CACCCUGGUCUAGAAAUGAGUUU 3' <- TEPI 
I I: : I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
9662 
I 
5' CACCCUGGUCUAG-AAA---UGAGUUU 3' <- TEPI 
I I I I I I I I I I I : I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
26 




5' UCUCCCAAAGGCUGGAUGAGUUU 3' <- TEP1 
I I I I I I I I: I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNA fold MFE Predicted Alignment 
10395 
I 
5' UCUCCCAAAGGCUGGAUGAGUUU 3' <- TEP1 
I I I I : : I : I I I I I : I 
3' GACAGCUUCAUUGGCG-ACUCGAU 5' <- svRNAb 
TEPl Result Remarks 
None of the TEPl predicted target sites look promising for functional binding sites. 70% of 
the seed matches are 6-mer matches with a G:U wobble pair, which is not a very good seed match. 
None of the matches have a MG value below -10, and most of the matches are above a -5 MG 
value. While the TEPl minor vault protein is required for a stable association between the vault 
RNA and the vault particle, and may help recruit the vault RNA into the vault particle, it does not 
appear that the small vault RNAs regulate the TEPl gene. 
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NFKBl 
Gene microRNA Position Seed 6GdlJElex 
NFKB13' UTR svRNAa 99 8:0:1 -24.96 
NFKB13' UTR svRNAa 266 7:0:1 -21.2 




5' AAGGUGCUCAGAGAGCCGGCCC 3' <- NFKBl 
I I : I : I I I I : I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3476 
I 
5' AAGGUGCUCAG--AGAGCCGGCCC 3' <- NFKBl 
: I I I I I : I I I I : I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' CUUACUAAGCUUUUGCCAGCUG 3' <- NFKBl 
I I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNA fold MFE Predicted Alignment 
3643 
I 
5' CUUACUAAGCUUUUGCCAGCUG 3' <- NFKBl 
I I I I I I I I I I I I : 





NFKB Result Remarks 
Both predicted seed matches for the NFKB 1 gene look very promising, especially the first 
ranking seed match. The first ranking seed match at position 3476 has an 8-mer seed match with 
one G:U wobble pair, and in its predicted MFE binding configuration there is 10 bases pairs in a 
row around the seed region, which would form a very strong bond. The position 3476 seed match 
has a very high ~Gduplex value of -24.96 and a MG value of -11.57. All but six of the bases in 
svRNAa bind to the target site on the NFKB mRNA in the MFE binding configuration, and the 
bases have good base pair probabilities. This target site is definitely a candidate for functional 
binding, and could be further investigated and tested to see if svRNAa will bind to the target site 
and regulate the NFKB 1 gene. 
The second target site, at position 3643, while not as promising as the first, still has potential 
to be a functional binding site for svRNAa. It does not have as low of a MG value (-6.5), but the 
~Gduplex value is good, at -21.2, and it is a 7-mer seed match with one G:U wobble pair, which is a 
good seed match. The predicted MFE binding configuration is a straight one-to-one base pairing of 
svRNAa on the target site, and base pair probabilities in the binding are very high. For these 
reasons, I believe the target site at position 3643 is a candidate for functional binding, even though 
the MG value is not as low as the recommended -10 value for functional binding. 
NFKB2 
No svRNAa or svRNAb seed matches were found on the NFKB2 mRNA. 
29 
RELA 
Gene microRNA Position Seed ~Gduplex ~Gopen 
RELA 3' UTR svRNAa 433 6:0:0 -14.9 -4.74 
RELA 3' UTR svRNAa 308 6:0:1 -15.22 -18.5 
RELA 3' UTR svRNAa 687 6:0:1 -19 -22.44 




5' AUAACGCCCCAGAUACCAGCCC 3' <- RELA 
I: I I: I I I I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
22 29 
I 
5' AUAACGCCC--CAGAUACCAGCCC 3' <- RELA 
I I I I: I I I I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' CCCCAUCCCCAUCCUCCAGCUU 3' <- RELA 
I I I I I I I I I : : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
2104 
I 
5' CCCCAUCCCCAUCCUCCAGCUU 3' <- RELA 
I I I I I : 











I I I I : I I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 
RNAfold MFE Predicted Alignment 
2104 
I 
3' <- RELA 
5' <- svRNAa 
5' CAGGCUGGCAGCUCU--CCAGUCA 3' <- RELA 
I I I I I I I I I I I I I I 
3' UGGCGAC--UCGAUUUCGGUCGGG 5' <- svRNAa 
RELA Result Remarks 
The predicted target sites for the RELA mRNA are not very promising for functional 
binding sites for svRNA. The top ranking target site, at position 2229, does have some potential for 
being functional binding site. The seed match is a 6-mer perfect match, but the ~Gduplex value for the 
target site is not very low, at only -14.9. The MG is low though, at -10.15, since the ~Gduplex value 
was relativity high, ~Gopen had to be high as well (which it was, at a value of -4.74). The base pair 
probabilities in the predicted MFE binding configuration are not very high, so it is unclear whether 
this target site could be a functional site or not. 
The other two predicted target sites are not good candidates for functional binding. They 
had very low ~Gopen values, causing them to have high MG values. It is unlikely that svRNAa 
would be able to bind to these target sites. 
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RELB 
Gene microRNA Position Seed 6Gduplex 
RELB 3' UTR svRNAa 104 6:0:1 -15.7 
RELB 3' UTR svRNAb 369 6:0:1 -9.3 




5' CUGAAGUGGACAUAUUCAGCCU 3' <- RELB 




3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
1970 
I 
5' CUGAAGUGGACAUAUUCAGCCU 3' <- RELB 
I I I I I: : I I I I I : 
3' UGGCGACU-CGAUUUC---GGUCGGG 5' <- svRNAa 




5' GUCUUCCCAAUAAAGAUGAGUUU 3' <- RELB 
1 I: I 11111:1 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
2 235 
I 
5' GUCUUCCCAAUAAAGAUGAGUUU 3' <- RELB 
II I I I : I I I I I : I 





RELB Result Remarks 
The predicted target sites for RELB do not have potential to be functional binding sites for 
the svRNAs. Their MG value is too high, and the base pair probabilities of the bases in the 
predicted MFE binding configuration are low. 
Gene microRNA Position Seed ~Gduple. ~Gopen ~~G 
REL 3' UTR svRNAa 477 6:0:0 -21.83 
REL3'UTR svRNAb 452 6:0:0 -16.9 
REL 3' UTR svRNAa 311 6:0:0 -18.11 




5' UCACACCACCGCACUCCAGCCU 3' <- REL 
1 11:1 111111: 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
2561 
1 
5 ' UCACACCACCGC---ACU----CCAGCCU 3 ' <-
II II 1 1 1 111111: 












I : I I I I I I I I I : 
3 ' GACAGCUUCAUUGGCGACUCGAU 
RNA fold MFE Predicted Alignment 
2536 
I 
3' <- REL 
5' <- svRNAb 
5' GAAGCAGAGGUUGC-AGUGAGCUG 3 ' <- REL 
I I I : I I : I I I I I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 




5' ACCAGGAAUUCGAGACCAGCCU 3' <- REL 
I I I I:: I: I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
2395 
I 
5' ACCAG-GAAUUCGAGACCAGCCU 3' <- REL 
I I I I I : I : I I I I I I I I : 
3' UGGCGACUCGAUUUC-GGUCGGG 5' <- svRNAa 
34 
REL Result Remarks 
The top ranking target site for REI_is a good candldate for functional binding of svRNAa to 
the target site at position 2561 of the REL mRNA. It has a low LiGJupb value of -21-83 and a low 
MG value of -9.78. The seed match is ~ perfect 6-mer nu.~ and the base pm- probabilities of the 
bases in the predicted MFE binding structure are high. 
The second best ranking target site for REI _ nu.y :u'<;Q be a o.ndldate for functional binding, 
except with svRNAb instead of svRNAa- While the MG value is somewhat high, at -4.62, the base 
pm probabilities of the predicted 1\fFE binding configuntion are quite high, and the MFE 
configuration has a 7 base pair (6-mer seed match plus 1 G :U wobble pair) and a 5 base pair 
sequence that nuke for ~ nice binding. Interesting, the target site for svRNAb (seed position 2536) 
on the REI, mRN A is only 10 nucleotides upstream from where svRN Aa binds to the predicted 
target site (seed position 2561). 
This makes me wonder if both these target sites are functional bindings sites, the first for 
svRNAa and the secoml for svRNAb, nuking this region of the 3' UTR a svRNA regub.tory region. 
Further investigation and testing could be done to verify whether these target sites are functional 
binding sites for svRNAa and sv1L~Ab. 
NLRP1 
Gene microRNA Position Seed LlGduplex LlGopen MG 
NLRP13' UTR svRNAa 181 6:0:1 -18.51 -17.23 -1.27 
35 




5' AUGCCACAGGGGGCCCCAGUCC 3' <- NLRP1 
I : I I I I I I I : I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
5158 
I 
5 ' AUGCCACAGGGGGCC----CCAGUCC 3' <- NLRP1 
: I I I I : I I 1111:11 
3' UGGCG--ACUCGAUUUCGGUCGGG 5 ' <- svRNAa 
NLRPI Result Remarks 
The predicted target site on the NI,RPl mRN A is most likely not a functional binding site 
for svRNAa.. The free energy lost when unpairing the target site from the mRNA secondary 
structure is almost as much as the free energy gained from binding svRN Aa to the target site, so this 
binding will prob2hly not happen. AL~, the seed match L" 6-mer match with one G:U wobble pair, 
which is not a very strong bond, and the base pair probabilities for the MFE binding configuration 




Gene microRNA Position Seed ~Gduplex ~Gopen 
PRKACB 3' UTR svRNAa 2216 6:0:1 -19.7 
PRKACB 3' UTR svRNAa 1092 6:0:1 -18.6 
PRKACB 3' UTR svRNAa 698 6:0:0 -21.6 
PRKACB 3' UTR svRNAa 2558 6:0:1 -15.7 
PRKACB 3' UTR svRNAa 2155 6:0:1 -12.9 
PRKACB 3' UTR svRNAa 2351 6:0:1 -10.8 
PRKACB 3' UTR svRNAb 19 7:0:0 -15.11 




5' GGUUUUGAGGGCUAUUCAGCCA 3' <- PRKACB 
: : :1111 1 :11111 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3506 
1 
5' GGUUUUGAGGGCUA--UUCAGCCA 3' <- PRKACB 
1:1111 :11111 






















5' AAAAAGAAGUUGUUUCCAGCUA 3' <- PRKACB 
I I I : I : I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
<RNAfold MFE Predicted Alignment 
238 2 
I 
5 ' AAAAAGAAGUUGUUUCCAGCUA 3' <- PRKACB 
I I I : I : I I I I I: 
3' UGGCGACU-CGAUUUCGGUCGGG 5' <- svRNAa 




5 ' UGAGUAAUGAAGUGACCAGCCU 
I : I - : I I I I I I: 
-
3' UGGCGACUCGAUUUCGGUCGGG 
RNAfold MFE Predicted Alignment 
1988 
I 
3' <- PRKACB 
5' <- svRNAa 
5' UGAGUAAUGAAGUGACCAGCCU 3' <- PRKACB 
I I I I : I : I I I I I I I I I : 
3' UGGCGACUCG--AUUUC---GGUCGGG 5' <- svRNAa 
38 
• 




5' ACUAUCAGUAUGAUCUCAGCCU 3' <- PRKACB 
I I : . I : I : I I I I I : . 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNA fold MFE Predicted Alignment 
3848 
I 
5' ACUA-UCAGUAUGAUCUCAGCCU 3 ' <- PRKACB 
I I : I I I : I : I : I I I I I: 
3' UGGCGACUCG-AUUUCGGUCGGG 5' <- svRNAa 




5' UGAAAUUACUAGUGCCCAGCUG 3' <- PRKACB 
I I : : : I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3445 
I 
5' UGAAAUUACUAGUGCCCAGCUG 3 ' <- PRKACB 
I I I: I I I I I I : 
3' UGGCGACUCGAUUUC-GGUCGGG 5' <- svRNAa 
39 





I I I : : I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 
RNAfold MFE Predicted Alignment 
3641 
I 
3' <- PRKACB 
5' <- svRNAa 
5' GUAACAUUCCCAGUU----UCAGCCA 3' <- PRKACB 
I I : I : I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' GGAACAAGAUGACAUCUGAGCUC 3' <- PRKACB 
I I: 1:11 1111111 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
1309 
I 
5' GGAACAAGAUGACAUCUGAGCUC 3' <- PRKACB 
1111:11 1111111 
3' GACAGCUUC-AUUGGCGACUCGAU 5' <- svRNAb 
40 
PRKACB Result Remarks 
The top three ranking predicted target sites for PRKACB seem like promising candidates for 
functional binding sites for svRNAa. All three have a M G value less than -10, and low LlGduplcx 
values. The top two target sites have 6-mer seed matches with one G:U wobble pair though. But the 
base pair probabilities of the bases in the predicted MFE binding configurations are high for all 
three target sites. These factors indicate that these target sites have potential to be a functional 
binding site for svRNAa, which could regulate the PRKACB gene. Further investigation and testing 
could be conducted to determine whether these predicted target sites are functional binding sites for 
svRNAa. 
The fourth ranking target site has a MG value of -8.9, which is near the recommended-tO 
M G value for functional binding sites. But the base pair probabilities for the bases in the MFE 
predicted binding configuration are very low, indicating that the target site is probably not a 
functional binding site. The rest of the predicted target sites are most likely nonfunctional, as their 
MG and LlGduplex values are high. 
IL10 (Interleukin 10) 
Gene microRNA Position Seed ~Gduplex ~Gopen ~~G 
. 
ILlO 3' UTR svRNAa 569 7:0:1 -22 -9.54 -12.45 
IllO 3' UTR svRNAb 385 8:0:1 -20.18 -9.24 -10.93 
ILI0 3' UTR svRNAa 691 6:0:0 -20.05 -11.55 -8.49 
IllO 3' UTR svRNAb 427 7:0:1 -14.05 -6.44 -7.6 
ILI0 3' UTR svRNAa 84 6:0:0 -20.1 -16.08 -4.01 
ILI0 3' UTR svRNAb 168 7:0:0 -11.1 -7.53 -3.56 
ILlO 3' UTR svRNAa 772 6:0:1 -16.82 -13.45 -3.36 
ILI0 3' Ul"R svRNAa 857 6:0:0 -21.81 -21.4 -0.4 
ILI0 3' UTR svRNAb 832 6:0:0 -16.6 -19.64 3.04 
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5' UCUUGAAAGCUGUGGCCAGCUU 3' <- ILIO 
I: 1111: :111111:: 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
1165 
I 
5' UCUUGAA-AGCUGUGGCCAGCUU 3' <- ILI0 
::1 1111: :111111:: 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 




5' CACGCUUUCUAGCUGUUGAGCUG 3' <- ILI0 
1 1 11:1:1:1111": 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
981 
I 
5' CACGCUUUCUAGCUGUUGAGCUG 3' <- ILI0 
11:1:1:111111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
42 
• 





: : I I I I I I I I: 
3' UGGCGACUCGAUUUCGGUCGGG 
RNAfold MFE Predicted Alignment 
1287 
I 
3' <- ILI0 
5 ' <- svRNAa 
5' GUCAGGAGUUCCUAACCAGCCU 3' <- ILI0 
I : I I I : I I I I I I I : 
3' UGGCG--ACUCGAUUUC-GGUCGGG 5' <- svRNAa 




5' UAAUUUAUCUUGUCUCUGGGCUU 3' <- ILI0 
I: I I: : I I I I : I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
1023 
I 
5' UAAUUUAUCUUGUC----- ----UCUGGGCUU 3' <- ILI0 
: I I I I I I I : I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
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5 ' UCUGGGAUAGCUGACCCAGCCC 3' <- ILIO 
I : I : I I I I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5 ' <- svRNAa 
RNA fold MFE Predicted Alignment 
680 
I 
~ 'UCUGGGAUAGCUGAC-CCAGCCC 3 ' <- ILIO 
I : I I I I I : I I I I I I I I 
3' UGGCGAC-UCGAUUUCGGUCGGG 5' <- svRNAa 




5' AUUUCUAUUUAUUUACUGAGCUU 3' <- ILIO 
I I I I I I :: I I I I I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
764 
I 
5' AUUUCUAUUUAUUUACUGAGCUU 3' <- ILIO 
I I I I I I I 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
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5' CGCGCACCUGUAAUCCCAGCUA 3' <- IL10 
I I I I I I I I I I I: 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfald MFE Predicted Alignment 
1368 
I 
5' CGCGCACCUGUAAUCCCAGCUA 3' <- IL10 
I I I I I : I I I I I : 
3' UGGCGACUCGAUUUC--GGUCGGG 5' <- svRNAa 




5' UCAUGCCCCUGUACUCCAGCCU 3' <- IL10 
I : I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfald MFE Predicted Alignment 
1453 
I 
5' UCAUGCCCCUGUACU----CCAGCCU 3' <- IL10 
: I I I I I I I I I I I I I : 
3' UGGCGACUCGAUUUCGGUCGGG 5 ' <- svRNAa 
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5' GAGAUGGAAGUUGCAGUGAGCUG 3 ' <- IL10 
I I I : I I I I I I I I : 
. 3' GACAGCUUCAUUGGCGACUCGAU 5 ' <- svRNAb 
RNAfold MFE Predicted Alignment 
1428 
I 
. 5' GAGAUGGAAGUUGC-AGUGAGCUG 3' <- IL10 
I I I I I : I I I I I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
IL10 Result Remarks 
The top three ranking target sites for IL10 seem like good candidates for functional binding 
sites for svRNAs. The top ranking target site, at position 1165, has a 7 -mer seed match with one 
G:U wobble, with a good MG value of -12.45 and a good LlGduplcx value of -22. All but 5 of the 
bases in svRNAa bind to the target site in the predicted MFE binding configuration. The second 
ranking target site has an 8-mer seed with one G:U wobble, and good values of 10.93 for MG and 
-20.18 for LlGduplcx' The predicted MFE binding configuration has 14 base pairs in a row on the 5' 
end of sTRNAb, forming a very nice bond to the target site. The third ranking target site has a 
perfect 6-mer seed match, with a good LlGduplcx value of -20.05, and a decent MG value of -8.49, 
slighdy below the recommended -10 value. These three target sites could be further investigated and 
tested to determine whether they are functional binding sites from svRNAs and svRNAb. 
The rest of predicted target sites from ILl 0 have litde likelihood of being functional binding 




Gene microRNA Position Seed ~Gduplex ~Gopen 
CXCL14 3' UTR svRNAb 343 7:0:0 -14.4 -5.36 
CXCL14 3' UTR svRNAb 373 6:0:0 -15.6 -12.36 
CXCL14 3' UTR svRNAb 475 7:0:1 -13.5 -16.01 
CXCL14 Position 1144 Seed Match (3' UTR Position 343) 
• Ali One-to-One gnment 
1144 
, 
5 ' UACGUCACUAUACAUCUGAGCUU 3' <- CXCL14 
: , , , 
""'" 3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
1144 
, 
5' UACGUCACUAU-ACAUCUGAGCUU 3' <- CXCL14 
, , , , , 
""'" 3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 




. 5' CGCCCGGGAGGAACAAUGAGCUU 3' <- CXCL14 
, II:: :,' 111111 
· 3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
1174 
, 
'5' CGCCCGGGAGGAACAA-UGAGCUU 3' <- CXCL14 
':11 "' 111111 











1 1 1 1 : I I : 111:111 
3' GACAGCUUCAUUGGCGACUCGAU 
RNAfold.MFE Predicted Alignment 
1276 
1 
3' <- CXCL14 
5' <- svRNAb 
5' CUGCCACGGGCUCUCCUGGGCUU 3' <- CXCL14 
III I :1 I: 111:111 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
CXCL14 Result Remarks 
The top ranking target site for CXCL14 is a good candidate for a functional binding site for 
svRNAb, which could regulate the CXCL14 gene. This would make sense for svRNAb to regulate 
CXCL14, since it plays a role in inflammation and in known to be found in breast cells. Persson et aL 
found CXCL14 to be upregulated in MCF-7 breast cancer cells, and they also found svRNAb to 
regulate the CYP3A4 gene in these MCF-7 cancer cells, so it makes sense that svRNAb would also 
regulate CXCL14 since it is so closely linked with breast cells. The target site on the CXCL14 
mRNA has a 7-mer perfect seed match with svRNAb, and has a good MG value of -9.03, near the 
recommended -10 value for functional binding sites. The base pair probabilities for the predicted 
MFE binding configuration are high, and the structure looks well formed with 3 groups of binding 
base pairs and two unpaired loops. Further investigation and testing could be done to verify whether 
this target site in a functional binding site for svRNAb. 
The other two predicted target sites have high MG values and low base pair probabilities 
for their predicted MFE binding configurations, and are therefore not likely functional binding sites. 
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ABCC4 
Gene microRNA Position Seed LlGduplex 
ABCC4 3' UTR svRNAb 1205 6:0:1 -18.11 
ABCC4 3' UTR svRNAb 1093 6:0:1 -12.89 
ABCC4 3' UTR svRNAa 158 6:0:1 -11.82 
ABCC43' UTR svRNAb 908 6:0:1 -15.01 




5' GGUGGCUGUAAUAUGUUGAGUUC 3' <- ABCC4 
/ :/:/1/1:/ 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
5302 
/ 
5' GGUGGCUGUAAUAUGUUGAGUUC 3' <- ABCC4 






3' GACAGCUUCAUUG-GCGACUCGAU 5' <- svRNAb 




5' UAAUAGCAUUGUCAUUUGGGCUU 3' <- ABCC4 
/ / / /: / :/1:/1/ 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
RNAfold MFE Predicted Alignment 
5190 
/ 
5 ' UAAUAGCAUUGUCAU--------UUGGGCUU 3' <-
: /I /I :/1:/1/ 








5' CUUAUCCAAGGAUCUCCAGCUC 3' <- ABCC4 
I I I I I I I : I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
4255 
I 
5' CUUAUCCAAGGAUCU----CCAGCUC 3' <- ABCC4 
I I I I I I I I I I I : I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 





I I : I I : I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 
RNAfold MFE Predicted Alignment 
5005 
I 
3' <- ABCC4 
5 ' <- svRNAb 
5' UGUAAGCCUUUUGGUUUGGGCUG 3' <- ABCC4 
: I I : I I I : 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 
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ABCC4 Result Remarks 
The top ranking target site on the ABCC4 mRNA, at position 5302, is a good candidate for 
functional binding of svRNAb. The seed match is only a 6-mer match with one G:U wobble pair, 
but the match has good values of -18.11 for L\GdupIex and -10.95 for MG. In the predicted MFE 
binding configuration, all but 6 of the svRNAb bases are paired with the target site, and 14 bases in 
a row are paired extending from the svRNAb seed The base pair probabilities in MFE configuration 
are very high also. Further investigation and testing could be done to verify whether the target site at 
position 5302 of the ABCC4 mRNA is a functional binding site for svRNAb. 
The other 3 predicted target sites are most likely not functional binding sites due to high 
MG values, and low base pair probabilities in the predicted MFE binding configurations. 
ABCG2 
Gene microRNA Position Seed flGduplex flGopen flfIG 
ABCG2 3' UTR svRNAa 1106 6:0:1 -14.4 -3.02 -11.37 
ABCG2 3' UTR svRNAa 1094 6:0:1 -12.1 -4.62 -7.47 
ABCG2 3' UTR svRNAb 1559 7:0:0 -16.2 -9.46 -6.73 
ABCG2 3' UTR svRNAa 1509 6:0:1 -9.83 -7.78 -2.04 
51 




5' UACUCAGCCAUUCUCCCAGUCA 3' <- ABCG2 
I: I I I I I I I : I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3567 
I 
5' UACUCAGCCAUUCUCCCAGUCA 3' <- ABCG2 
I I I I I I I I I : I 
3' UGGCGACUCGAUUUC--GGUCGGG 5' <- svRNAa 




5' CACACAAAAGCCUACUCAGCCA 3' <- ABCG2 
I I I I: I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
RNAfold MFE Predicted Alignment 
3555 
I 
5' CACACAAAAGCCUAC-UCAGCCA 3' <- ABCG2 
I I I I I : I I I I I 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
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5 ' ACUUACAGGAGUUAACUGAGCUG 
I I : I : : 1111111: 
3' GACAGCUUCAUUGGCGACUCGAU 
RNAfold MFE Predicted Alignment 
4020 
I 
3' <- ABCG2 
5' <- svRNAb 
5' ACUUACAGGAGUUAA--CUGAGCUG 3' <- ABCG2 
1:111 1111111: 
3' GACAGCUUCAUUGGCGACUCGAU 5' <- svRNAb 





I : I I I : II II I 
3' UGGCGACUCGAUUUCGGUCGGG 
RNAfold MFE Predicted Alignment 
3970 
I 
3' <- ABCG2 
5' <- svRNAa 
5' GAGACCACAUUUCAU---CUAGCCC 3' <- ABCG2 
III I 1:11111 
3' UGGCGACUCGAUUUCGGUCGGG 5' <- svRNAa 
53 
ABCG2 Result Remarks 
The top ranking target site of ABCG2, at position 3567, is a potential functional binding site 
from svRNAa, although it is not a very promising site. It has a relatively high ~GdupIex value, and 
while it has a low MG value, this is only due to a very high ~Gopen value. The seed match for the 
target site is only a 6-mer match with a G:U wobble pair. The base pair probabilities of the predicted 
MFE binding configuration are not extremely high. So while the target site at position 3567 is a 
potential functional biding site, it is not the best candidate, and I recommend focusing on other 
potential target sites in other genes before further investigation of this target site. 
The other target sites of ABCG2 show little potential for being a functional binding site for 
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